Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease
Susan M. Webb(Universitat Autònoma de Barcelona), Mônica R. Gadelha(Universidade Federal do Rio de Janeiro), James Signorovitch(Analysis Group (United States)), Lesly Portocarrero-Ortíz(Universitat Autònoma de Barcelona), John E. Ware(Unknown), Wojciech Zgliczyński(Postgraduate School of Molecular Medicine), Xavier Badı́a(Universitat de Barcelona), Min Yang(Analysis Group (United States)), Anna Forsythe, Lauren Nelson(RTI Health Solutions), Christophe De Block(University of Antwerp), Mario Maldonado, Lori McLeod(RTI International)
Cited by 29
Related Papers
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
|Journal of Clinical Epidemiology|1998|2.9k
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research
|Quality of Life Research|2013|855
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
|Circulation|2018|837